EUVIMEDEUVIMED entdecken
Open Access

Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma

Evan K Noch iD, Laura N Palma, Isaiah Yim, Nayah Bullen, Yuqing Qiu, Hiranmayi Ravichandran, Junbum Kim, Andre Rendeiro, Melissa B Davis, Olivier Elemento, David J Pisapia, Kevin Zhai und 5 weitere

Neuro-Oncology · 2023

DOI: 10.1093/neuonc/noad117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Evan K Noch und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuro-oncology, Department of Neurology, Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Hyperglycemia, Metformin. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Insulin feedback is a critical mechanism responsible for the poor clinical efficacy of phosphatidylinositol 3-kinase (PI3K) inhibition in cancer, and hyperglycemia is an independent factor associated with poor prognosis in glioblastoma (GBM). We investigated combination anti-hyperglycemic therapy in a mouse model of GBM and evaluated the association of glycemic control in clinical trial data from patients with GBM.

Methods

The effect of the anti-hyperglycemic regimens, metformin and the ketogenic diet, was evaluated in combination with PI3K inhibition in patient-derived GBM cells and in an orthotopic GBM mouse model. Insulin feedback and the immune microenvironment were retrospectively evaluated in blood and tumor tissue from a Phase 2 clinical trial of buparlisib in patients with recurrent GBM.

Results

We found that PI3K inhibition induces hyperglycemia and hyperinsulinemia in mice and that combining metformin with PI3K inhibition improves the treatment efficacy in an orthotopic GBM xenograft model. Through examination of clinical trial data, we found that hyperglycemia was an independent factor associated with poor progression-free survival in patients with GBM. We also found that PI3K inhibition increased insulin receptor activation and T-cell and microglia abundance in tumor tissue from these patients.

Conclusion

Reducing insulin feedback improves the efficacy of PI3K inhibition in GBM in mice, and hyperglycemia worsens progression-free survival in patients with GBM treated with PI3K inhibition. These findings indicate that hyperglycemia is a critical resistance mechanism associated with PI3K inhibition in GBM and that anti-hyperglycemic therapy may enhance PI3K inhibitor efficacy in GBM patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHyperglycemiaMetforminHumansAnimalsMicePhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesInsulinFeedbackRetrospective StudiesCell ProliferationHypoglycemic AgentsCell Line, TumorTumor Microenvironment

Stichwörter der Autor:innen

glioblastomahyperglycemiainsulinmetforminphosphatidylinositol 3-kinase

Substanzen

Phosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesInsulinMetforminHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Neuro-oncology, Department of Neurology, Weill Cornell Medicine, New York, New York, USA.
  • Sandra and Edward Meyer Cancer Center, Weill Department of Medicine, New York, New York, USA.
  • Department of Population Health Sciences, Division of Biostatistics and Epidemiology, Weill Cornell Medicine, New York, New York, USA.
  • Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York, USA.
  • Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York, USA.
  • Research Center for Molecular Medicine of the Austrian Academy of Sciences, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Evan K Noch

Förderung

  • NIH HHS
  • NCI NIH HHS
  • NINDS NIH HHS
  • Roland and Gladys Harriman Foundation Bridge Fund
  • Society for Neuro-oncology/PRIME Oncology Young Investigator
  • National Institutes of Health
  • Stand Up To Cancer-American Association for Cancer Research DT22-17
  • Weill Cornell Medicine

Zitieren

APA

Noch, E. K., Palma, L. N., Yim, I., Bullen, N., Qiu, Y., Ravichandran, H., Kim, J., Rendeiro, A., Davis, M. B., Elemento, O., Pisapia, D. J., Zhai, K., LeKaye, H. C., Koutcher, J. A., Wen, P. Y., Ligon, K. L., & Cantley, L. C. (2023). Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad117

Vancouver

Noch EK, Palma LN, Yim I, Bullen N, Qiu Y, Ravichandran H, et al. Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma. Neuro-Oncology. 2023. doi:10.1093/neuonc/noad117

BibTeX
@article{Noch2023,
  author = {Noch, Evan K and Palma, Laura N and Yim, Isaiah and Bullen, Nayah and Qiu, Yuqing and Ravichandran, Hiranmayi and Kim, Junbum and Rendeiro, Andre and Davis, Melissa B and Elemento, Olivier and Pisapia, David J and Zhai, Kevin and LeKaye, Hongbiao Carl and Koutcher, Jason A and Wen, Patrick Y and Ligon, Keith L and Cantley, Lewis C},
  title = {Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma},
  journal = {Neuro-Oncology},
  year = {2023},
  doi = {10.1093/neuonc/noad117}
}
Kostenlos starten →